Kornimate/medical-research-clean huggingface dataset:
spinal structure and mobility in chronic obstructive pulmonary disease

Conditions: COPD; Postural; Defect; Respiratory Function Impaired; Dyspnea

Summary: in recent studies with musculoskeletal system disorders in chronic respiratory patients, it has been reported that postural control is affected in copd patients. the aim of this study to investigate relationship between spinal structure and mobility an severity of dyspnea in patients with copd.

chronic obstructive pulmonary disease (copd) is a preventable and treatable disease characterized by irreversible airway limitation. in recent studies with musculoskeletal system disorders in chronic respiratory patients, it has been reported that postural control is affected in copd patients.it has been observed that balance systems, functional balance tests, posturography, posture assessment systems, force platform and inclinometer measurements are used in studies on postural control assessment in copd patients.there are a limited number of studies in which devices that objectively present the degree of deviation in spinal curves are used in patients with copd, and posture and lung volume and capacities are evaluated. therefore, the aim of this study is to investigate the changes in spine structure and mobility in copd patients and to reveal their relationship with static and dynamic lung volumes and capacities.

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study * be over 18 years old * being clinically stable * not having a copd attack in the last 3 months at least exclusion criteria: * refusing to participate in the research * having had spinal surgery presence of back and shoulder pain * idiopathic scoliosis * ankylosing spondylitis * presence of respiratory disease other than copd * difficulty understanding verbal commands

Keywords: copd posture respiratory function dyspnea
irofulven in treating patients with stage iv melanoma

Conditions: Melanoma (Skin)

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of irofulven in treating patients who have stage iv melanoma.

objectives: i. determine the response rate and duration of response in patients with stage iv malignant melanoma treated with 6-hydroxymethylacylfulvene. ii. determine the toxicity of this regimen in these patients. outline: this is a multicenter study. patients receive 6-hydroxymethylacylfulvene iv over 5 minutes on days 1-5. treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. patients with stable or responding disease after completion of course 2 receive additional courses. patients are followed every 3 months for 5 years, and then annually thereafter until death. projected accrual: approximately 16-35 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: histologically proven stage iv malignant melanoma no prior chemotherapy or no more than 1 prior chemotherapy containing regimen measurable disease brain metastasis allowed if adequately treated patient characteristics: age: 18 and over performance status: ecog 0-2 or karnofsky 60-100% life expectancy: not specified hematopoietic: hemoglobin at least 10 g/dl wbc at least 4,000/mm3 absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than upper limit of normal (uln) alt/ast no greater than 2.5 times uln renal: creatinine no greater than 1.5 mg/dl or creatinine clearance at least 50 ml/min other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: see disease characteristics recovered from any prior therapy no other concurrent therapy

Keywords: stage iv melanoma
restoration of permanent molars affected with molar-incisor-hypomineralization (mih) among a group of egyptian children using composite restorations or preformed metal crowns

Conditions: Molar Incisor Hypomineralization

Summary: the aim of this study is to compare the clinical outcome of using direct esthetic composite restorations and the use of preformed metal crowns in managing mih cases among a group of egyptian children.


Eligibility criteria:
inclusion criteria: * children with mih in one fully erupted molar or more. * age ranging from 7-12 years. * cooperative children * good general health. exclusion criteria: * patients participating in other experiments. * patients with parents planning to move away within the following year. * patients with only mildly affected mih molars that do not require extensive restorative treatment. * mih-affected molars that have a very poor prognosis and require extraction. * first permanent molars that are affected with other developmental defects, such as hypoplasia, dental fluorosis or amelogenesis imperfecta
study of the nevisense device to assess atypical skin lesions

Conditions: Nevus; Multiple Nevi; Large Acquired Nevi; Skin Lesion

Summary: the purpose of this study is to find out whether the nevisense device can provide useful information about atypical moles to complement the usual assessments done during routine screening for melanoma. assessing particpants' moles with the nevisense device may help improve screening methods for the early detection of melanoma in people with atypical mole syndrome.


Eligibility criteria:
inclusion criteria: * adult patients (\> 30 years of age) at the time of the initial study visit. * patients displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (lan) \> 5 mm in diameter. these patients have "atypical mole syndrome", which is a high-risk nevus phenotype and the target patient population in this study. * patients with at least three clinically stable nevi between 5 and 20 mm in diameter. * patients (or lar) who are able to provide informed consent. * patients with previous total body photography images taken at least 3 years prior exclusion criteria: * patients without at least three clinically stable nevi between 5 and 20 mm in diameter. * patients with any electronic implantable devices. * patients who are pregnant (verbally confirmed with the participant).

Keywords: atypical skin lesions skin lesions multiple nevi large acquired nevi memorial sloan kettering cancer center 20-010
limited-english proficiency (lep) virtual reality (vr) study

Conditions: Anxiety; Parents; Language

Summary: the purpose of this study is to determine if non-invasive distracting devices (virtual reality headset) are more effective than the standard of care (i.e., no technology based distraction) for preventing anxiety in parental and pediatric populations with limited english proficiency (lep).


Eligibility criteria:
inclusion criteria: * ages 0-99 (child participants will be ages 0 to 17. parents of children of any age may also be enrolled) * able to consent * self-identified as having a limited english proficiency or english-proficiency exclusion criteria: * people who do not consent * significant cognitive impairment * history of severe motion sickness * current nausea * seizures * visual problems * patients whose children are clinically unstable or require urgent/emergent intervention

Keywords: virtual reality
lift with or without injection of bm-mncs

Conditions: Anal Fistula

Summary: to improve the outcome of lift, some authors used a combined approach of lift. pooled analysis of seven studies including 192 patients revealed a success rate of 83.5 % after combined lift approach. the use of bone marrow aspirate concentrate (bmac) in surgery is not entirely new as it has been widely used in the treatment of bone defects, mandibular reconstruction, maxillary sinus augmentation and in critical limb ischemia. a previous study concluded that the use of bmac to augment external anal sphincter repair strengthens wound healing by transferring cells responsible for healing directly to the site of repair. the current study aimed to assess the outcome of local injection of bone marrow mononuclear cells (bm-mncs) in conjunction with lift as compared to lift alone in regards to healing rate, time to healing, and ultimate success rate.


Eligibility criteria:
inclusion criteria: * adult patients of either gender presented with cryptoglandular trans-sphincteric anal fistula exclusion criteria: * patients with secondary anal fistula * immunocompromised patients * patients with previous pelvic radiotherapy * pregnant women * patients with asa (american society of anesthesiologists) iii or higher.
home based electrical stimulation on post-stroke lower limb tightness.

Conditions: Spasticity as Sequela of Stroke

Summary: spasticity is a common complication post stroke. post-stroke spasticity along with weakness and lack of coordination result in gait abnormalities and functional limitations. recent treatment option include neuromuscular electric stimulation (nmes), a form of therapy that applies electrical currents to produce contraction of innervated muscle by depolarizing local motor nerves. currently, there are wide varieties of nmes devices available commercially for consumer. the main purpose of this study is to evaluate the feasibility and acceptability of a home-based nmes program on lower limb spasticity in patient with post-stroke more than 6 months and to assess the impact of the program. this is single arm prospective intervention study. patient will apply home-based nmes on their leg for 20 minutes, 5 days a week for 4 weeks. at the end of the study, an outcome measures will be assessed and patient will be required to answer a questionnaires on their experience.


Eligibility criteria:
inclusion criteria: 1. post stroke (hemorrhagic or ischemic) with ankle plantarflexor (gastrocnemius and soleus) spasticity mas 1+ to mas 3, 2. post stroke more than 6 months, 3. at least 18 years old, 4. able to ambulate 10 meter either independently or aided (single point stick or quadripod) 5. compliant to outpatient therapy. 6. minimal cognitive (mmse\> 24) and minimal sensory impairment, 7. stable neurological and medical condition exclusion criteria: 1. introduction or changes in anti-spastic medication dose within 3 months or during study period, 2. receiving intervention for spasticity (eg bont or serial casting) within 3 months or during research period, 3. new neurological condition/disease, 4. presence of contraindications to nmes, which is: pregnancy, malignancy, presence of electronic implant eg cardiac pacemaker, cardioverter defibrillator, uncontrolled seizure/epilepsy, infected tissues/ tuberculosis or osteomyelitis, impaired lower limb circulation/ dvt/ thrombophlebitis, recent fracture or osteoporosis, actively bleeding tissue or person with untreated hemorrhagic disorder, damaged or skin diseases at the affected lower limb
the effects of aerobics training on balance in patients with multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: standing balance, with and without blindfold, will be measured on patients with multiple sclerosis using a biodex balance scale. a twelve week intervention with one non impact aerobics group and one control group will be performed. standing balance will then be retested on all subjects and the results will be statistically compared.

standing balance will be tested in 4 phases: * on a firm surface eyes open * on a frim surface eyes blindfolded * on a foam surface eyes open * on a foam surface eyes blindfolded the aerobics classes will be conducted by a nia (non impact aerobics) instructor and will be a combination of tai chi, slow movement dancing, stretching and modified yoga stretches.

Eligibility criteria:
inclusion criteria: * patients that were diagnosed by a neurologist with relapsing remitting multiple sclerosis. * edss scale between 1 and 6. * patients that are able to travel to and from a 12 week program location. exclusion criteria: * patients that were diagnosed by a neurologist with primary or secondary progressive multiple sclerosis. * edss scale above 6

Keywords: multiple sclerosis non impact aerobics
an investigation of small intestinal carcinoid carcinoma in families

Conditions: Carcinoid Carcinoma

Summary: this proposed pilot study is to conduct detailed interviews into the medical, environmental, and family histories the second phase of this study project is to and to collect blood specimen to obtain dna. the blood specimen and dna will be processed by the rutgers university cell and dna repository (rucdr) and stored for a second phase of this pilot. the purpose is to rule out familial multiple endocrine neoplasia (men 1), and succinate dehydrogenase complex, subunit d (sdhd), gene inactivation thought to be associated with different types of carcinoid cancer.

there have not been any studies published which specifically describe the medical, environmental, and genetic factors in carcinoid tumors cases that have carcinoid in family members. while rare, with an incidence of four per 100, 000, carcinoid represents the most frequent malignancy affecting the small intestine. because nearly half (49%) of the cases of gastrointestinal carcinoid tumors have hepatic metastasis at diagnosis, identification of the risk factors associated with carcinoid has the potential to increase early diagnosis and cure. carcinoid tumors are thought to occur spontaneously and not associated with an inherited genetic abnormality that would increase a family member's risk for developing carcinoid cancer. there is a known inherited genetic abnormality that is associated with bronchial carcinoid tumors but only less than 10%. gastrointestinal carcinoid tumors are not thought to be associated with a inherited genetic abnormality. there have been several small studies that have examined gastrointestinal carcinoid in multiple family members. it remains uncertain if these cases of carcinoid in multiple family members are characteristic of a heritable or environmental etiology. most carcinoid cancer is not inherited; however, less than 10% of neuroendocrine carcinoid cancer is thought to be due to a change (called a "mutation") in a gene inherited from a parent. there are several genes that are suspected to be associated with carcinoid cancer, two of interest in this study is the multiple endocrine neoplasia type1 (men1), and succinate dehydrogenase complex, subunit d (sdhd) genes.

Eligibility criteria:
inclusion criteria: 1. over the age of 18 years 2. history of biopsy confirmed small intestinal carcinoid tumor 3. english speaking 4. mentally and emotionally capable of answering questions 5. willing and available for study participation 6. at least one first-degree family member with carcinoid tumor exclusion criteria: 1. if you are under the age of 18 years, 2. if you have any mental or memory impairments 3. if you are unable to understand the information in the informed consent document.

Keywords: carcinoid familial collect and describe information about the medical and environmental factors associated with each cases of carcinoid carcinoma develop a genogram representing the family cancer history of cases of carcinoid.
treatment of hypertrophic scars with intradermal botox

Conditions: Hypertrophic Scar

Summary: this is a prospective, open label, single center, self-controlled clinical study to demonstrate the safety and efficacy of intradermal botulinum toxin in treating hypertrophic scarring.


Eligibility criteria:
inclusion criteria: 1. healthy female and male subjects between the ages 18-75. 2. non-smoker. 3. fitzpatrick skin type i-vi. 4. desire to improve hypertrophic scarring. 5. able and willing to comply with all visit, treatment and evaluation schedules and requirements. 6. able to understand and provide written informed consent. exclusion criteria: 1. pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding. 2. presence of any active systemic or local infections. 3. presence of active local skin disease that may alter wound healing. 4. known allergy to botulinum toxin. 5. history of smoking in past 10 years. 6. history of chronic drug or alcohol abuse. 7. inability to understand the protocol or to give informed consent. 8. history of cosmetic treatments in the area to be treated, including injectable filler of any type within the past year; botox in the treatment area within the past 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep peels within the past 6 months; surgery to the area within the past 6 months. 9. history of intralesional corticosteroids or any other injectable medication to the area within the last 3 months. 10. history of topical corticosteroids to the area within the past 4 weeks. 11. history of any musculoskeletal disease or any weakness in the area to be treated. 12. as per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
card for community pharmacy vaccinations - phase 2

Conditions: Vaccination; Vaccination Pain; Vaccination Reaction; Vaccination Pharmacy

Summary: this study is phase 2 of a cluster trial integrating the card (comfort ask relax system) in community pharmacies affiliated with wholehealth pharmacy partners. it involves continuing card in pharmacies randomized to card in phase 1 of the trial (2023-2024 fall/winter vaccination season), and initiating card in pharmacies randomized to control (usual care) in phase 1 of the trial. both groups will use card for delivery of vaccinations during the 2024-2025 fall/winter vaccination season.

this study is a continuation of a previous cluster trial. pharmacies that participated in the original trial will be asked if they want to volunteer for the present study. they will all use the card system as the vaccination delivery system for their community pharmacies during the 2024-2025 fall/winter vaccination season. they will collect feedback from vaccine clients using a paper survey that tracks experiences, including symptoms, during vaccination. the responses will be compared between groups. the sample size is limited by the number of pharmacies that volunteer. we expect 8 pharmacies will participate in a 1:1 ratio (about 1/3 of all pharmacies in original cluster trial), with a total of at least 500 vaccination clients. we will collect data for all vaccinations that are conducted and for which client feedback data are available. thus, the sample size is expected to deviate from the estimated sample size of 500.

Eligibility criteria:
inclusion criteria: * clients undergoing vaccination in participating pharmacies and providers working in participating pharmacies exclusion criteria: * able to speak and write in english

Keywords: vaccination reaction vaccination experience
comparison of percutaneous mechanical thrombectomy with different access in treatment of acute deep venous thrombosis

Conditions: Deep Vein Thrombosis

Summary: the study aims to compare the modified approach through ipsilateral deep calf venous access of contralateral femoral venous access with the traditional approach through ipsilateral popliteal venous access for mixed type deep venous thrombosis (dvt), and determine whether it can achieve similar therapeutic effects as central type dvt.

acute deep venous thrombosis (dvt) is associated with development of post-thrombotic syndrome (pts). early removal of iliofemoral thrombosis by percutaneous mechanical thrombectomy (pmt) may reduce the incidence of pts. in general, pmt is performed through ipsilateral popliteal venous access as a traditional approach. however, the thrombosis in distal popliteal vein cannot be removed. previous study demonstrated that the residual thrombus may decrease the efficacy of pmt. the study aims to compare the modified approach through ipsilateral deep calf venous access of contralateral femoral venous access with the traditional approach for mixed type dvt, and determine whether it can achieve similar therapeutic effects as central type dvt. the purpose of this study is to obtain high-level evidence for the endovascular treatment of acute dvt.

Eligibility criteria:
inclusion criteria: 1. age between 18-85 years old; 2. acute dvt occurred no more than 14 days since the onset of disease; 3. dvt treated by percutaneous mechanical thrombectomy 4. informed consent signed by patients. exclusion criteria: 1. patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent; 2. women during pregnancy and lactation; 3. patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\<6 months); 4. patients who are unable or unwilling to participate in the study.

Keywords: deep venous thrombosis percutaneous mechanical thrombectomy post-thrombotic syndrome
relapse prevention study in newly abstinent smokers

Conditions: Substance Dependence

Summary: the purpose of this study is to determine the effect of gsk598809 as compared to placebo in preventing recently-quit smokers from going back to smoking.

the primary objective of this study is to evaluate the efficacy of gsk598809 compared to placebo for the prevention of relapse to smoking in recently abstinent smokers. subjects who meet eligibility criteria will enter a 4-week open label treatment period during which they will receive nicotine replacement therapy (nrt). subjects who have achieved at least one week of abstinence during the last week of an open label treatment period will be randomized to either gsk598809 or placebo in the double-blind treatment period and followed for another 12 weeks.

Eligibility criteria:
inclusion criteria: * has smoked at least 10 cigarettes a day for at least 2 years * has had multiple previous attempts to quit smoking and relapsed to smoking. * generally healthy exclusion criteria: * cannot be using smokeless tobacco of any type or has tried to quit with medicine. * does not abuse alcohol or drugs * certain emotional problems being treated with medications * pregnant or breast feeding female

Keywords: nicotine dependence smoking pharmacological treatment relapse prevention
compare elp in patients with elective phaco-vtx surgery in one eye and a single lens phaco surgery on the other eye

Conditions: Macular Pucker

Summary: the aim of the study is to gain more insight into the potential impact of a vitrectomy (removal of the vitreous) on postoperative effective position of the intraocular lens (iol). moreover, this study can provide very useful information for the optimal lens calculation in patients undergoing lens extraction with iol implantation (whether or not combined with a vitrectomy) should undergo.

* comparison elp post phaco vtx (pucker / floaters) versus post phaco and use this information to develop a customized iol calculation for eyes undergoing phacovtx. * evidence for recording lens thickness (lt) parameter in the iol strength calculation in kws (in the calculation of the elp in the light of the olsen formula, using the c-constant) in order to be able to make an even more accurate prediction of the post-operative diopter target of the patient.

Eligibility criteria:
inclusion criteria: * age \> 50 yrs * macular pucker wherefore vitrectomy is necessary exclusion criteria: * macular pathology other than macular pucker * corneal pathology * other ocular pathology that could affect the biometrics or elp * previous vitrectomy in one of the eyes